IA
AARD

IFP Advisors’s Aardvark Therapeutics AARD Stock Holding History

IFP Advisors’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.58K Buy
447
+426
+2,029% +$1.99K ﹤0.01% 4119
2026
Q1 		$79 Buy
+21
New +$218 ﹤0.01% 4775

Other funds holding AARD

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

IFP Advisors's AARD Position: Q2 2026 in Review

IFP Advisors increased its Aardvark Therapeutics (AARD) stake by 2,029% in Q2 2026, buying an estimated $1.99K and bringing the position to 447 shares worth $2.58K. The position accounts for ﹤0.01% of the portfolio, ranked #4119.

IFP Advisors first reported a position in AARD in Q1 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • IFP Advisors held 447 shares of Aardvark Therapeutics worth $2.58K as of Q2 2026.
  • IFP Advisors bought 426 Aardvark Therapeutics shares in Q2 2026, an estimated $1.99K.
  • Aardvark Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4119 holding.
  • IFP Advisors first reported a position in Aardvark Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.